BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
59.00
+1.65 (2.88%)
At close: Jun 26, 2026, 4:00 PM EDT
58.60
-0.40 (-0.68%)
After-hours: Jun 26, 2026, 7:59 PM EDT
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,221 employees as of December 31, 2025. The number of employees increased by 181 or 5.95% compared to the previous year.
Employees
3,221
Change (1Y)
181
Growth (1Y)
5.95%
Revenue / Employee
$1,006,618
Profits / Employee
$83,434
Market Cap
11.40B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3,221 | 181 | 5.95% |
| Dec 31, 2024 | 3,040 | -361 | -10.61% |
| Dec 31, 2023 | 3,401 | 319 | 10.35% |
| Dec 31, 2022 | 3,082 | 37 | 1.22% |
| Dec 31, 2021 | 3,045 | -14 | -0.46% |
| Dec 31, 2020 | 3,059 | 58 | 1.93% |
| Dec 31, 2019 | 3,001 | 152 | 5.34% |
| Dec 31, 2018 | 2,849 | 268 | 10.38% |
| Dec 31, 2017 | 2,581 | 288 | 12.56% |
| Dec 31, 2016 | 2,293 | 135 | 6.26% |
| Dec 31, 2015 | 2,158 | 477 | 28.38% |
| Dec 31, 2014 | 1,681 | 340 | 25.35% |
| Dec 31, 2013 | 1,341 | 252 | 23.14% |
| Dec 31, 2012 | 1,089 | 87 | 8.68% |
| Dec 31, 2011 | 1,002 | 131 | 15.04% |
| Dec 31, 2010 | 871 | 151 | 20.97% |
| Dec 31, 2009 | 720 | 71 | 10.94% |
| Dec 31, 2008 | 649 | 124 | 23.62% |
| Dec 31, 2007 | 525 | 115 | 28.05% |
| Dec 31, 2006 | 410 | 96 | 30.57% |
| Dec 31, 2005 | 314 | -45 | -12.53% |
| Dec 31, 2004 | 359 | 87 | 31.99% |
| Dec 31, 2003 | 272 | 53 | 24.20% |
| Dec 31, 2002 | 219 | 3 | 1.39% |
| Dec 31, 2001 | 216 | 42 | 24.14% |
| Dec 31, 2000 | 174 | 25 | 16.78% |
| Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Krystal Biotech | 295 |
BMRN News
- 12 days ago - BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia - TheFly
- 12 days ago - BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 - PRNewsWire
- 19 days ago - Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer - TheFly
- 25 days ago - BioMarin Pharmaceutical Transcript: AGM 2026 - Transcripts
- 4 weeks ago - 3 Best Stocks to Buy This Week, According to Analysts – May 25-May 29 - TipRanks
- 5 weeks ago - BioMarin price target lowered to $111 from $116 at Canaccord - TheFly
- 5 weeks ago - BioMarin's drug shows significant growth gains in children in late-stage trial - Reuters
- 5 weeks ago - BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial - TheFly